KDIGO Updates Blood Pressure Guideline for Nondialysis CKD
The new KDIGO guideline recommendation to target a systolic blood pressure of less than 120 mm Hg in many patients with nondialysis CKD is lower than the 2012 target recommended in 2012.
The new KDIGO guideline recommendation to target a systolic blood pressure of less than 120 mm Hg in many patients with nondialysis CKD is lower than the 2012 target recommended in 2012.
The approval was based on data from the double-blind, parallel-group, active-controlled phase 3 PARAGON-HF trial.
Study findings show that the survival and cardiovascular benefits of a healthy lifestyle extend to individuals with reduced kidney function who are at higher risk for cardiovascular disease.
In a study, 1 in 4 male veterans with prostate cancer failed to receive a comprehensive assessment of their cardiovascular risk factors.
Vascular calcification is the most likely mechanism underlying the association between hyperphosphatemia and mortality, according to investigators.
Patients with HFrEF who have low systolic blood pressure and renal dysfunction were found to have better survival outcomes when treated with all 3 guideline-directed pharmacotherapies.
Risk prevention efforts and increased surveillance and monitoring of patients with nondialysis-dependent CKD are needed, according to investigators.
Patients with HFrEF who were diabetic or prediabetic had reduced left ventricular volumes following therapy with empagliflozin.
Women have lower odds of receiving LIMA graft to the LAD artery, undergoing complete vascularization, receiving multi-arterial grafting
Energy intake during hospital stay was found to be an independent predictor of mortality among elderly patients with heart failure.